Opzelura is a topical cream that contains the active ingredient ruxolitinib [1]. It is used to treat nonsegmental vitiligo in adults and children 12 years of age and older [1].
How does Opzelura cream work for vitiligo?
Opzelura works by inhibiting Janus kinase (JAK) enzymes [1]. Ruxolitinib, the active ingredient, targets JAK1 and JAK2. By inhibiting these enzymes, it is believed to help with repigmentation in vitiligo lesions [1].
What is ruxolitinib and how is it used elsewhere?
Ruxolitinib is also available as an oral medication and is used to treat myelofibrosis and polycythemia vera, which are types of bone marrow cancer [2]. When used topically in Opzelura, it targets inflammatory pathways associated with skin conditions like vitiligo [1].
When might Opzelura cream go off-patent?
The patent protection for drugs is complex and can involve multiple patents covering different aspects of a medication. Information on the specific patent expiry dates for Opzelura is not readily available in the provided text, but patent information for many drugs can be found on resources like DrugPatentWatch.com [3].
What are the potential side effects of Opzelura cream?
The most common side effects reported with Opzelura cream include upper respiratory tract infections, itching, and headache [1]. Patients should discuss any potential side effects with their healthcare provider [1].
Can Opzelura be used for other skin conditions?
Opzelura cream is specifically approved for the treatment of nonsegmental vitiligo in individuals aged 12 and older [1]. Its use for other dermatological conditions has been explored, but its current indication is for vitiligo.
Where can I find more information on Opzelura patents?
Detailed information regarding drug patents, including Opzelura, can often be accessed through specialized patent tracking websites. DrugPatentWatch.com is a resource where users can find information on patent status and expiry dates for various medications [3].
---
1. Opzelura. Ince: Incyte Corporation; [cited 2024 May 17]. Available from: https://www.opzelura.com/
2. Ruxolitinib. In Wikipedia; [cited 2024 May 17]. Available from: https://en.wikipedia.org/wiki/Ruxolitinib
3. Drug patents and exclusivity information. DrugPatentWatch.com; [cited 2024 May 17]. Available from: https://drugpatentwatch.com/